Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.19
-0.0200-0.32%
Pre-market: 6.640.4500+7.27%04:06 EDT
Volume:986.33K
Turnover:6.05M
Market Cap:425.43M
PE:-2.66
High:6.31
Open:6.18
Low:6.00
Close:6.21
Loading ...

EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $27 From $29

THOMSON REUTERS
·
12 Nov 2024

EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

EyePoint price target lowered to $22 from $30 at H.C. Wainwright

TIPRANKS
·
11 Nov 2024

EyePoint Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $22 From $30

THOMSON REUTERS
·
11 Nov 2024

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
09 Nov 2024

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
07 Nov 2024

BRIEF-EyePoint Pharmaceuticals Reports Q3 2024 Financial Results And Highlights Recent Corporate Developments

Reuters
·
07 Nov 2024

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

EyePoint Pharmaceuticals Q3 Operating Expenses USD 43.272 Million

THOMSON REUTERS
·
07 Nov 2024

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

THOMSON REUTERS
·
07 Nov 2024

EyePoint Pharmaceuticals Inc: $161.0 Mln Oversubscribed Equity Financing Extends Cash Runway Into 2027

THOMSON REUTERS
·
07 Nov 2024

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire
·
07 Nov 2024

EyePoint Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing

Simply Wall St.
·
05 Nov 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
04 Nov 2024

Press Release: EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Dow Jones
·
01 Nov 2024